Program
laroprovstat
Also written as “AZD0780”, “FDC laroprovstat/Rosuvastatin 1” and “FDC laroprovstat/Rosuvastatin 2”.
Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Cardiovascular Diseases · Hyperlipidemias · Atherosclerosis, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 227 open or running | phase 3since Dec 2, 2024 | May 17, 2022 | Jan 4, 2027phase 3 · NCT07000136 |
- Named in AstraZeneca’s own pipeline as
laroprovstat
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel, fortrea and quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since May 17, 2022.
- Sep 23, 2024Phase 1 study in DyslipidemiasNCT06671405 · 59 enrolled · United States
- Oct 28, 2024Phase 2 study in AtherosclerosisNCT06692764 · 202 enrolled · United States
- Dec 2, 2024Phase 3 study in DyslipidemiasNCT06834932 · 432 enrolled · China, Hong Kong
- Dec 16, 2024Phase 1 study in DyslipidemiasNCT06742853 · 81 enrolled · United States, United Kingdom
- May 23, 20253 phase 3 studiesNCT07000136, NCT07000123, NCT07000357
- Oct 10, 2025Phase 1 study in DyslipidemiasNCT07216131 · 14 enrolled · United States
- Oct 17, 2025Phase 2 study in DyslipidemiasNCT07218900 · 76 enrolled · Russia
- Dec 19, 2025Phase 1 study in HyperlipidemiasNCT07316608 · 44 enrolled · United States
- Feb 13, 2026Phase 1 study in DyslipidemiasNCT07423598 · 40 enrolled · United States
- Mar 31, 2026Phase 1 study in DyslipidemiasNCT07513571 · 31 enrolled · United States
- May 26, 20262 phase 3 studies in HypercholesterolemiaNCT07619131, NCT07619118
- May 28, 2026Phase 1 study in HyperlipidemiasNCT07622433 · 18 enrolled · United States
- Nov 5, 2026Phase 3 study in HypercholesterolemiaNCT07930507 · 204 planned · China, Hong Kong, Malaysia and more
- Nov 13, 2026Primary completion moved from 2025-07-03 to 2027-02-22Date moved laterphase 3 · +20 months · NCT06834932
Ahead
- Jan 4, 2027Primary completion: phase 3 study in Heterozygous Familial HypercholesterolaemiaNCT07000136
- Jan 11, 2027Primary completion: phase 3 study in Cardiovascular DiseasesNCT07000123
- Feb 22, 2027Primary completion: phase 3 study in DyslipidemiasNCT06834932
- May 28, 2027Primary completion: phase 3 study in HypercholesterolemiaNCT07619118
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07930507Hypercholesterolemia · China, Hong Kong, Malaysia and more | 3 | Not yet recruiting | Oct 11, 2027 | 204 |
| NCT07622433Hyperlipidemias · United States | 1 | Completed | Sep 6, 2026 | 18 |
| NCT07619131Hypercholesterolemia · United States, Bulgaria, Canada and more | 3 | Recruiting | Jul 30, 2027 | 600 |
| NCT07619118Hypercholesterolemia · United States, Australia, Canada and more | 3 | Recruiting | May 28, 2027 | 200 |
| NCT07513571Dyslipidemias · United States | 1 | Completed | Jul 8, 2026 | 31 |
| NCT07423598Dyslipidemias · United States | 1 | Completed | Jun 29, 2026 | 40 |
| NCT07316608Hyperlipidemias · United States | 1 | Completed | Jun 5, 2026 | 44 |
| NCT07218900Dyslipidemias · Russia | 2 | Completed | Sep 3, 2026 | 76 |
| NCT07216131Dyslipidemias · United States | 1 | Completed | Dec 30, 2025 | 14 |
| NCT07000357Cardiovascular Diseases · United States, Argentina, Brazil and more | 3 | Recruiting | Oct 26, 2029 | 15,100 |
| NCT07000136Heterozygous Familial Hypercholesterolaemia · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 4, 2027 | 473 |
| NCT07000123Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 11, 2027 | 3,103 |
| NCT06742853Dyslipidemias · United States, United Kingdom | 1 | Completed | Oct 29, 2025 | 81 |
| NCT06834932Dyslipidemias · China, Hong Kong | 3 | Active, not recruiting | Feb 22, 2027 | 432 |
| NCT06692764Atherosclerosis · United States | 2 | Completed | Apr 18, 2025 | 202 |
| NCT06671405Dyslipidemias · United States | 1 | Completed | Feb 17, 2025 | 59 |
| NCT06576765Hepatic Impairment · United States | 1 | Completed | Nov 8, 2024 | 16 |
| NCT06592482Renal Insufficiency · United States | 1 | Completed | Dec 1, 2024 | 30 |
| NCT06173570Dyslipidemias · United States, Canada, Czechia and more | 2 | Completed | Sep 30, 2024 | 428 |
| NCT05817461Cardiovascular Diseases · United Kingdom | 1 | Completed | Jun 6, 2023 | 8 |
| NCT05787002Dyslipidemias · United States | 1 | Completed | May 15, 2023 | 16 |
| NCT05384262Dyslipidemias · United States, United Kingdom | 1 | Completed | Jun 14, 2024 | 183 |
How it is read
Names in the registry
- “AZD0780”, 17 entries
- “FDC laroprovstat/Rosuvastatin 1”, 1 entry
- “FDC laroprovstat/Rosuvastatin 2”, 1 entry
- “laroprovstat/rosuvastatin 1”, 1 entry
- “laroprovstat/rosuvastatin 2”, 1 entry
Conditions, from the studies’ own filings
- Dyslipidemias, 10 studies
- Hypercholesterolemia, 3 studies
- Cardiovascular Diseases, 3 studies
- Hyperlipidemias, 2 studies
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.